Paradigm shift in pharma R&D brought about by the COVID-19 pandemic | Article

API Solutions

Dr. Reddy's API business supplies high-quality, affordable APIs to leading generic formulations manufacturers and is the preferred API partner for pharma companies in more than 100 countries.

R&D

Dr. Reddy’s supplies generic APIs to 80+ countries, excelling in R\&D across niche molecules and key therapies, with capabilities from lab to production in contained/non-contained APIs and advanced chemical processes.

White Paper

Dr. Reddy’s offers insightful whitepapers sharing expertise on APIs, formulations, regulatory trends, and industry innovations, helping global pharma partners gain knowledge, solve challenges, and drive faster, compliant product development.

A Paradigm Shift that Is Here to Stay - Sauri Gudlavalleti speaks to CME Manager on COVID-19 response

September 14, 2020

Sauri Gudlavalleti, Global Head of Integrated Product Development Organization (IPDO), Dr. Reddy’s spoke to CME Manager on the paradigm shift in pharma R&D brought about by the COVID-19 pandemic.

To read the article, click here

View More Articles

A Paradigm Shift that Is Here to Stay - Sauri Gudlavalleti speaks to CME Manager on COVID-19 response

A Paradigm Shift that Is Here to Stay - Sauri Gudlavalleti speaks to CME Manager on COVID-19 response

Contact Us

OR

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patents Act (Bolar Exemption) and not for commercial sale.